Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 3/20 | 0.64 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.64 |
| ▸ | FABP3 | P05413 | 1/20 | 0.64 |
| ▸ | FNTA | P49354 | 1/20 | 0.63 |
| ▸ | FNTB | P49356 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 3/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31367787 | 1.00 | FABP4 (0.64) | FABP4FABP5FABP3FNTAFNTB | |
| SCHEMBL14160820 | 0.92 | CTNNB1 (0.55) | FABP4FABP5FABP3FNTAFNTB | |
| SCHEMBL1002948 | 0.89 | FABP4 (0.67) | FABP4FABP5FABP3FNTAFNTB | |
| SCHEMBL13301256 | 0.87 | ACHE (0.52) | FABP4FABP5FABP3FNTAFNTB | |
| SCHEMBL11823172 | 0.87 | MAPT (0.57) | FABP4FABP5FABP3FNTAFNTB | |
| SCHEMBL11604659 | 0.86 | ALDH1A1 (0.71) | FABP4FABP5FABP3FNTAFNTB | |
| SCHEMBL11821506 | 0.84 | MAPT (0.69) | FABP4FABP5FABP3FNTAFNTB | |
| SCHEMBL1128275 | 0.83 | FNTA (0.68) | FABP4FABP5FABP3FNTAFNTB | |
| SCHEMBL29937494 | 0.82 | F10 (0.53) | FABP4FABP5FABP3FNTAFNTB | |
| SCHEMBL3202252 | 0.82 | KDM4E (0.69) | KDM4EALDH1A1MAPTHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3625316-B1 | DISPERSANTS, METHOD OF MAKING, AND USING SAME | CHEVRON ORONITE CO (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-110621766-B | Dispersant, method of manufacture and use thereof | 雪佛龙奥伦耐有限责任公司 | 2021-12-24 | — | — | CN | disclosed |
| US-10815446-B2 | Dispersants, method of making, and using same | CHEVRON ORONITE COMPANY LLC (US) | 2020-10-27 | — | — | US | disclosed |
| EP-3625316-A1 | DISPERSANTS, METHOD OF MAKING, AND USING SAME | Chevron Oronite Company LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-110621766-A | Dispersant, method of manufacture and use thereof | 雪佛龙奥伦耐有限责任公司 | 2019-12-27 | — | — | CN | disclosed |
| EP-2456757-B1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-2456757-B1 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV ILLINOIS (US) | 2019-05-01 | — | — | EP | disclosed |
| US-20180334635-A1 | DISPERSANTS, METHOD OF MAKING, AND USING SAME | CHEVRON ORONITE COMPANY LLC | 2018-11-22 | — | — | US | disclosed |
| WO-2018211466-A1 | DISPERSANTS, METHOD OF MAKING, AND USING SAME | CHEVRON ORONITE COMPANY LLC (US) | 2018-11-22 | — | — | WO | disclosed |
| US-8748451-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2014-06-10 | — | — | US | disclosed |
| US-8431538-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431538-B2 | HDAC inhibitors and therapeutic methods of using same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120252740-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME | KOZIKOWSKI ALAN (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252740-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME | KOZIKOWSKI ALAN (US) | 2012-10-04 | — | — | US | disclosed |
| US-20120252740-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME | KOZIKOWSKI ALAN (US) | 2012-10-04 | — | — | US | disclosed |
| EP-2456757-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | The Board of Trustees of the University of Illinois (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011011186-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011011186-A2 | HDAC INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-01-27 | — | — | WO | disclosed |
| US-3988208-A | FOR GLUCOSE | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-10-26 | — | — | US | disclosed |
| US-3975398-A | INDICATOR FOR DETERMINATION OF GLUCOSE | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252740-A1 | HDAC INHIBITORS AND THERAPEUTIC METHODS OF USING SAME | HDAC1, HDAC9, HDAC5 | FABP4 3757/4885FABP5 2195/4885FABP3 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.